BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23388130)

  • 1. Pediatric mast cell sarcoma of temporal bone with novel L799F (2395 C>T) KIT mutation, mimicking histiocytic neoplasm.
    Kim YS; Wu H; Pawlowska AB; Bautista-Quach MA; Huang Q; Gaal K; Chang KL
    Am J Surg Pathol; 2013 Mar; 37(3):453-8. PubMed ID: 23388130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mast cell sarcoma of the scalp: the first sign of undisclosed systemic mastocytosis?
    Falleti J; Borgia L; Lalinga AV; De Cecio R; Natella V; Patitucci G; Vita G
    Pathol Res Pract; 2012 Nov; 208(11):683-6. PubMed ID: 22963840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mast cell sarcoma in an infant: a case report and review of the literature.
    Bautista-Quach MA; Booth CL; Kheradpour A; Zuppan CW; Rowsell EH; Weiss L; Wang J
    J Pediatr Hematol Oncol; 2013 May; 35(4):315-20. PubMed ID: 23211696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
    Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature.
    Georgin-Lavialle S; Aguilar C; Guieze R; Lhermitte L; Bruneau J; Fraitag S; Canioni D; Chandesris MO; Suarez F; Grandpeix-Guyodo C; Damaj G; Barete S; Aouba A; Fite C; Robert C; Gaulard P; Lortholary O; Tournilhac O; Dubreuil P; Hermine O
    J Clin Oncol; 2013 Feb; 31(6):e90-7. PubMed ID: 23129735
    [No Abstract]   [Full Text] [Related]  

  • 6. Systemic mastocytosis (SM) and associated malignant bone marrow histiocytosis - a hitherto undescribed form of SM-AHNMD.
    Rudzki Z; Sotlar K; Kudela A; Starzak-Gwóźdź J; Horny HP
    Pol J Pathol; 2011; 62(2):101-4. PubMed ID: 21866466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
    Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
    Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
    Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
    Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation.
    McClintock-Treep SA; Horny HP; Sotlar K; Foucar MK; Reichard KK
    J Clin Pathol; 2009 Dec; 62(12):1147-9. PubMed ID: 19729359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
    Shivakrupa R; Bernstein A; Watring N; Linnekin D
    Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.
    Zavodovskaya R; Liao AT; Jones CL; Yip B; Chien MB; Moore PF; London CA
    Am J Vet Res; 2006 Apr; 67(4):633-41. PubMed ID: 16579756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
    Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
    J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mastocytosis.
    Metcalfe DD
    Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mast cell sarcoma: new cases and literature review.
    Monnier J; Georgin-Lavialle S; Canioni D; Lhermitte L; Soussan M; Arock M; Bruneau J; Dubreuil P; Bodemer C; Chandesris MO; Lortholary O; Hermine O; Damaj G
    Oncotarget; 2016 Oct; 7(40):66299-66309. PubMed ID: 27602777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of allelic imbalance at the c-kit gene locus and c-kit overexpression by immunohistochemistry in pediatric osteosarcomas.
    Entz-Werlé N; Marcellin L; Gaub MP; Guerin E; Schneider A; Berard-Marec P; Kalifa C; Brugiere L; Pacquement H; Schmitt C; Tabone MD; Jeanne-Pasquier C; Terrier P; Dijoud F; Oudet P; Lutz P; Babin-Boilletot A
    J Clin Oncol; 2005 Apr; 23(10):2248-55. PubMed ID: 15800315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.
    Mital A; Piskorz A; Lewandowski K; Wasąg B; Limon J; Hellmann A
    Eur J Haematol; 2011 Jun; 86(6):531-5. PubMed ID: 21362052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).
    Sotlar K; Colak S; Bache A; Berezowska S; Krokowski M; Bültmann B; Valent P; Horny HP
    J Pathol; 2010 Apr; 220(5):586-95. PubMed ID: 20112369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.